manilatimes7h
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical” or "the Company”, "we”, or "our”), a commercial-stage ...
STAT10h
FDA commissioner suggests RFK Jr. and Trump might compromise an agency ‘at peak performance’
The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s ...
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...
manilatimes15h
OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting
OrganOx Ltd., a medical technology company developing innovative solutions for organ preservation, and eGenesis, Inc., a ...